CALGARY, ALBERTA -- (MARKET WIRE) -- March 05, 2007 -- Resverlogix Corp. (TSX: RVX) (“Resverlogix”) is pleased to announce that it has initiated a research program dedicated to ApoA-I production and its therapeutic potential for disorders that effect cognitive function such as Alzheimer’s Disease (AD). Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases such as Alzheimer’s. Resverlogix has molecules potent and selective in raising plasma ApoA-I/HDL by increasing ApoA-I production that may beneficially impact AD. The Alzheimer’s program will be developed in RVX Therapeutics’, a wholly owned subsidiary of Resverlogix Corp. and does not signal a change in any other processes or programs currently underway at Resverlogix.
